FBXO32 and type 1 diabetes mellitus: Our findings could suggest that targeting the ubiquitin–proteasome system, Ampk and muscle‐specific E3 ubiquitin ligases such as Atrogin‐1 and Traf6 may be an effective strategy for molecular and clinical intervention in the muscle wasting pathological process in T1DM.